Despite the uncertainty on the political front and the macroeconomic unknowns, the biotech sector's fundamentals have remained solid.
Partner insight BB Biotech AG, one of the largest biotech investors in Europe, has weathered the past eighteen months and all the volatility comparatively well. This positive performance has continued into 2017. The total return for BB Biotech's share price in Q1 this year was 7.4% in CHF and 7.0% in EUR. The portfolio showed an overall gain of 12.6% in CHF, 12.3% in EUR and 14.5% in USD. "Regulatory approvals of biotech drugs, successful clinical trials involving new treatment approaches and ongoing takeover activity suggest that the biotech industry will continue to deliver double-d...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
!['I do not think the Bank will be able [to lower rates] because I do not think inflation will come down much further or much faster. I think we are stuck with a fairly sticky inflation situation,' she said.](https://image.chitra.live/api/v1/wps/4f6ccd8/e30bef9b-445c-417a-ba61-becfaf9ed6fb/19/bank-of-england-2-323x202.jpg)
